The receipt of this Import and Market permission paves way for the launch of Acalabrutinib 100mg capsules (Calquence®) in India, subject to the receipt of related statutory approvals and licenses.
Acalabrutinib 100mg capsules is indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).